Advanced

Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?

Björkqvist, Maria LU (2016) In Journal of Neurochemistry 137(5). p.670-672
Abstract

This Editorial highlights a study published in the current issue of Journal of Neurochemistry by Dobson et al. (), investigating whether the immunomodulatory agent, laquinimod exerts an immunomodulatory effect on isolated Huntington´s disease monocytes. In Huntington´s disease (HD) a central immune activation is mirrored in the periphery by a low-grade immune response and monocytes isolated from HD gene carriers have been shown pathologically hyperreactive in response to stimulation. This hyperreactive immune system has become recognized as an important feature of HD pathogenesis and the employment of a strategy to affect this hyperreactivity could be a potential disease-modifying avenue in HD. Read the highlighted article 'Laquinimod... (More)

This Editorial highlights a study published in the current issue of Journal of Neurochemistry by Dobson et al. (), investigating whether the immunomodulatory agent, laquinimod exerts an immunomodulatory effect on isolated Huntington´s disease monocytes. In Huntington´s disease (HD) a central immune activation is mirrored in the periphery by a low-grade immune response and monocytes isolated from HD gene carriers have been shown pathologically hyperreactive in response to stimulation. This hyperreactive immune system has become recognized as an important feature of HD pathogenesis and the employment of a strategy to affect this hyperreactivity could be a potential disease-modifying avenue in HD. Read the highlighted article 'Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells' on doi: 10.1111/jnc.13553.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Neurochemistry
volume
137
issue
5
pages
670 - 672
publisher
Wiley-Blackwell
external identifiers
  • Scopus:84963664736
ISSN
1471-4159
DOI
10.1111/jnc.13539
language
English
LU publication?
yes
id
74c7db68-2875-4b93-ae9f-b1ce79527015
date added to LUP
2016-05-03 14:54:58
date last changed
2017-01-01 08:24:31
@misc{74c7db68-2875-4b93-ae9f-b1ce79527015,
  abstract     = {<p>This Editorial highlights a study published in the current issue of Journal of Neurochemistry by Dobson et al. (), investigating whether the immunomodulatory agent, laquinimod exerts an immunomodulatory effect on isolated Huntington´s disease monocytes. In Huntington´s disease (HD) a central immune activation is mirrored in the periphery by a low-grade immune response and monocytes isolated from HD gene carriers have been shown pathologically hyperreactive in response to stimulation. This hyperreactive immune system has become recognized as an important feature of HD pathogenesis and the employment of a strategy to affect this hyperreactivity could be a potential disease-modifying avenue in HD. Read the highlighted article 'Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells' on doi: 10.1111/jnc.13553.</p>},
  author       = {Björkqvist, Maria},
  issn         = {1471-4159},
  language     = {eng},
  month        = {04},
  number       = {5},
  pages        = {670--672},
  publisher    = {Wiley-Blackwell},
  series       = {Journal of Neurochemistry},
  title        = {Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?},
  url          = {http://dx.doi.org/10.1111/jnc.13539},
  volume       = {137},
  year         = {2016},
}